Related Experiment Video
Updated: May 17, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
HDR brachytherapy combined with interstitial hyperthermia in locally advanced cervical cancer patients initially
Agnieszka Zolciak-Siwinska1, Joanna Jonska-Gmyrek, Jagna Staniaszek
1Department of Brachytherapy, Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, Roentgena Street 5, Warsaw, Poland. agnieszka.zolciak@wp.pl
Background And Purpose:
The aim of this study was to investigate whether hyperthermia (HT) combined with interstitial brachytherapy (ISBT) has any influence on acute and late side effects in patients with advanced cervical cancer. Local control (LC) and disease-free survival (DFS) were also analysed.
Materials And Methods:
Following the completion of radiochemotherapy, patients with cervical cancer (FIGO stages I-III) were assigned to two treatment groups, either ISBT combined with interstitial hyperthermia (ISHT) or ISBT alone as a control group. Selection criterion for the ISBT combined with HT group was advanced cervical cancer with poor response to external beam radiotherapy. A total of 76 patients were included in the statistical analysis. Once a week, HT (at a temperature above 42.5°C) was administered for 45 min before and during high dose rate (HDR) brachytherapy (BT) in 43 patients. Four HT treatments were administered.
Results:
The median follow-up time was 43 months (range 4-73 months). Significant differences were not observed for the distribution of early and late complications between the HT and no HT groups. Despite this, LC was similar in both groups. The 5-year DFS for the BT and BT + HT groups was 73.6% and 65.8%, respectively. The 5-year LC for the BT and BT + HT groups was 89% and 83%, respectively. For the majority of patients the maximum temperature level of 44-45°C was achieved during the ISHT.
Conclusions:
ISHT is well tolerated and does not affect treatment-related early or late complications.
